Moreover, it was demonstrated in some cancers that higher HDAC expression might be associated with poor prognosis—for example, in prostate carcinoma, a higher HDAC2 expression is associated with shorter relapse time [31]. This evidence concerns the gene HDAC2 and prostate carcinoma.